News Releases | Merck Newsroom Home

By Date
By Category
Consumer Care News
Vaccine News
Research and Development News
Corporate News
Financial News
Corporate Responsibility News

By Date

Merck Announces $5 Billion Accelerated Share Repurchase
5/21/13 5:00 pm EDT
Merck to Present at the UBS Global Healthcare Conference
5/17/13 3:45 pm EDT
Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently
5/17/13 8:30 am EDT
Merck Prices $ 6.5 Billion Debt Offering
5/15/13 6:29 pm EDT
Merck for Mothers Launches Initiative in India to Reduce the Number of Women Dying During Pregnancy and Childbirth
5/14/13 4:23 pm EDT
Merck to Present at the Bank of America/Merrill Lynch 2013 Healthcare Conference
5/14/13 9:15 am EDT
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Merck’s HPV Vaccine, Available to Developing Countries through UNICEF Tender
5/9/13 7:20 am EDT
Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
5/8/13 8:30 am EDT
Merck and Celebrity Chef Art Smith “Cook Up a Recipe” for Better Type 2 Diabetes Management
5/7/13 10:33 am EDT
FDA Approves Merck’s LIPTRUZET™ (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol
5/3/13 3:06 pm EDT
Merck Announces First-Quarter 2013 Financial Results
5/1/13 7:00 am EDT
Supplemental_Earnings_Package_1Q13.pdf (189.7 KB)
Merck Announces New $15 Billion Share Repurchase Program
5/1/13 6:58 am EDT
Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture Claims
4/29/13 5:00 pm EDT
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
4/29/13 7:30 am EDT
Merck Named a Top 50 Company for Diversity by DiversityInc
4/24/13 4:43 pm EDT
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
4/24/13 7:30 am EDT
Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™
4/23/13 6:39 am EDT
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
4/22/13 7:30 am EDT
Merck Opens New Manufacturing Facility in Hangzhou, China
4/16/13 8:00 am EDT
Merck Announces FDA Acceptance of New Drug Application for an Investigational Tablet Formulation of the Antifungal NOXAFIL® (posaconazole)
4/10/13 8:30 am EDT
Merck to Present New Data on VICTRELIS® (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting
4/8/13 10:37 am EDT
Merck to Hold First-Quarter 2013 Sales and Earnings Conference Call on May 1
4/1/13 8:30 am EDT
Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet
3/27/13 8:00 am EDT
Mistrial Declared in FOSAMAX® (alendronate sodium) New Jersey State Court Trial
3/18/13 2:07 pm EDT
Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease
3/13/13 8:30 am EDT
Merck Provides Update on IMPROVE-IT Trial
3/12/13 8:00 am EDT
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial
3/11/13 9:30 am EDT
Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
3/9/13 12:50 pm EST
Merck Announces Appointment of Roger M. Perlmutter, M.D., Ph.D., As President of Merck Research Laboratories; Peter S. Kim, Ph.D., to Retire
3/7/13 7:30 am EST
Merck Receives 2013 ENERGY STAR Sustained Excellence Award
3/6/13 8:30 am EST
Merck to Present at the 33rd Annual Cowen Health Care Conference
3/5/13 8:30 am EST
Merck Scientist Daria Hazuda Presents Bernard Fields Lecture at 20th Conference on Retroviruses and Opportunistic Infections (CROI)
3/4/13 9:59 am EST
Bruce Kuhlik and Merck Honored by PBI for Commitment to Pro Bono
2/28/13 9:43 am EST
Merck Announces Second-Quarter 2013 Dividend
2/26/13 2:29 pm EST
Merck to Present at the Citi 2013 Global Healthcare Conference
2/26/13 8:30 am EST
Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets
2/22/13 8:30 am EST
Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement
2/20/13 7:00 am EST
Merck Resolves Securities Class-Action Lawsuits Related to the ENHANCE Trial
2/14/13 8:00 am EST
Merck Statement on Venezuelan Currency Devaluation
2/13/13 9:00 am EST
Merck to Present at the Leerink Swann 2013 Global Healthcare Conference
2/12/13 8:30 am EST
Renowned Photographer and HIV Activist Duane Cramer Partners with Project Runway Star Mondo Guerra and Merck on I Design Campaign
2/7/13 9:04 am EST
Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
2/1/13 7:00 am EST
Supplemental_Earnings_Package_4Q12.pdf (440.15 KB)
FDA Approves OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women
1/25/13 11:30 am EST
Merck Provides Update on Next Steps for TREDAPTIVE™ (extended-release niacin/laropiprant)
1/11/13 7:39 am EST
Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
1/7/13 8:00 am EST
Merck to Present at the 31st Annual J.P. Morgan Healthcare Conference
1/4/13 8:30 am EST
Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets
1/2/13 4:45 pm EST
Merck to Present at 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
1/2/13 8:30 am EST
Merck Announces Fourth-Quarter 2012 Sales and Earnings Conference Call
1/2/13 8:00 am EST
Merck Announces HPS2-THRIVE Study of TREDAPTIVE™ (Extended-Release Niacin/Laropiprant) Did Not Achieve Primary Endpoint
12/20/12 8:30 am EST
Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program
12/18/12 7:30 am EST
The JAMA Network and Merck Announce Strategic Collaboration
12/3/12 10:40 am EST
Merck Initiates Phase II/III Study of Investigational BACE Inhibitor, MK-8931, for Treatment of Alzheimer's Disease
12/3/12 6:30 am EST
Merck Launches Maternal Health Awareness Campaign, Once Upon a Birth, with Actress Melissa Joan Hart
11/29/12 9:02 am EST
Merck Provides Update on EU Marketing Authorization Application for Ridaforolimus
11/29/12 8:00 am EST
Mondo Guerra of Project Runway All Stars Unveils One-of-a-Kind Clothing Design in Honor of World AIDS Day
11/28/12 10:35 am EST
Merck Increases Quarterly Dividend
11/27/12 2:57 pm EST
Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer
11/27/12 8:30 am EST
Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma
11/11/12 2:00 pm EST
Merck Reports New Phase III Analyses on Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy, Including Cirrhotic Patients
11/10/12 9:00 am EST
Interim Phase II Data of Merck's Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
11/10/12 9:00 am EST
Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine
11/8/12 8:30 am EST
Merck and Regenstrief Institute Establish Evidence-Based Care Collaboration
11/8/12 8:00 am EST
Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus
11/2/12 2:00 pm EDT
Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related to Vioxx
11/1/12 6:00 pm EDT
Merck Announces Third-Quarter 2012 Financial Results
10/26/12 7:00 am EDT
Supplemental_Earnings_Package_3Q12.pdf (586.49 KB)
Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment for Controlled Ovarian Stimulation
10/23/12 2:15 pm EDT
VICTRELIS® (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent
10/17/12 7:30 am EDT
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus
10/15/12 3:00 am EDT
Merck Researchers Present BMD Data from a Phase II Study of Odanacatib, Merck’s Investigational Cat-K Inhibitor for Post-Menopausal Osteoporosis
10/13/12 12:15 pm EDT
On World Sight Day, Merck and Partners Mark 25 Years of Successful Collaboration To Help Eliminate River Blindness
10/11/12 8:00 am EDT
Merck to Move Global Headquarters Within New Jersey
10/9/12 8:10 am EDT
Phase IIb Data Showed Merck’s Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes
10/3/12 8:46 am EDT
Merck to Present New Data for VICTRELIS® (boceprevir) and MK-5172 at The American Association for the Study of Liver Diseases 2012 Annual Meeting
10/1/12 11:12 am EDT
Merck to Hold Third-Quarter 2012 Sales and Earnings Conference Call on October 26
9/26/12 8:00 am EDT
Merck to Present at the UBS Global Life Sciences Conference
9/19/12 8:00 am EDT
Merck Announces Continued Commitment to Global Responsibility
9/13/12 8:08 am EDT
Merck Highlights Ongoing Commitment to Developing Medicines Targeting Infectious Disease at 52nd Annual ICAAC
9/12/12 8:08 am EDT
Merck Prices $2.5 Billion Debt Offering
9/10/12 7:00 pm EDT
Merck Announces New Phase III Data for Suvorexant, an Investigational Insomnia Medicine
9/10/12 8:30 am EDT
Merck to Present at Morgan Stanley Global Healthcare Conference
9/10/12 8:00 am EDT
Republic of Uganda and Merck Launch Cervical Cancer Vaccination Program
9/4/12 8:08 am EDT
Merck Provides Update on Cardiovascular Development Programs
8/26/12 8:00 am EDT
Merck Announces Second-Quarter 2012 Financial Results
7/27/12 7:00 am EDT
Supplemental_Earnings_Package_2Q12.pdf (343.9 KB)
Merck Recognizes World Hepatitis Day with Partnerships and Grants to Support Global and U.S. Hepatitis C Communities
7/26/12 8:08 am EDT
Merck, Collaborators Publish Study Showing Potential for Eradication of Persistent HIV Virus in the Body
7/25/12 5:00 pm EDT
Merck Announces Fourth-Quarter 2012 Dividend
7/24/12 12:34 pm EDT
Merck Signs Two Deals for Novel HIV Drug Candidates and Initiates Phase II Clinical Trial of MK-1439 for HIV
7/24/12 8:00 am EDT
ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks
7/22/12 3:00 pm EDT
Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
7/19/12 8:08 am EDT
Fashion Designer and Project Runway All Stars Winner Mondo Guerra Collaborates with Merck to Help Empower People with HIV to Work with Their Doctors to "Tailor" Their Treatment Plan
7/17/12 9:00 am EDT
Merck Launches Richard T. Clark Fellowship Program with PSI Partnership
7/17/12 8:08 am EDT
Merck Highlights Data Presentations at the Alzheimer’s Association International Conference, 2012
7/13/12 5:00 pm EDT
Update on Phase III Trial for Odanacatib, Merck's Investigational Cat-K Inhibitor for Osteoporosis
7/11/12 5:12 pm EDT
Merck Announces Collaboration to Improve Maternal Health through Expanded Access to Family Planning
7/11/12 10:15 am EDT
Merck to Hold Second-Quarter 2012 Sales and Earnings Conference Call on July 27
6/27/12 8:00 am EDT
Merck and AstraZeneca Agree to Amend Partnership
6/27/12 7:00 am EDT
Merck Statement on CDC Advisory Committee on Immunization Practices' Recommendation for Pneumococcal Vaccination in Immunocompromised Adults
6/20/12 1:23 pm EDT
Geisinger and Merck to Collaborate on Multi-year Effort to Improve Patient Adherence, Engagement and Care Delivery
6/18/12 8:30 am EDT
Merck to Present at Wells Fargo Securities Research and Economics 2012 Health Care Conference
6/18/12 8:00 am EDT
U.S. District Court Rules Against Merck in NASONEX® (mometasone furoate monohydrate) Patent Lawsuit
6/15/12 5:05 pm EDT
New Partnership With U.S. and Norwegian Governments and the Private Sector Formed to Save the Lives of Mothers and Their Newborn Children
6/14/12 8:08 am EDT
New Phase III Data Showed Merck’s Investigational Insomnia Medicine Suvorexant Improved Patients' Ability to Fall Asleep and Stay Asleep
6/13/12 8:00 am EDT
Merck Receives Complete Response Letter from U.S. Food and Drug Administration for Investigational Medicine Ridaforolimus
6/5/12 4:35 pm EDT
Merck to Present at Jefferies 2012 Global Healthcare Conference
6/1/12 8:00 am EDT
Merck to Present at Sanford C. Bernstein 28th Strategic Decisions Conference
5/30/12 8:00 am EDT
Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus
5/25/12 7:18 am EDT
Merck Announces Third-Quarter 2012 Dividend
5/22/12 12:50 pm EDT
FDA Approves New Labeling for ISENTRESS® (raltegravir) to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability with ISENTRESS in Combination Therapy in Previously Untreated Adult Patients Infected with HIV-1
5/21/12 8:00 am EDT
Merck to Present at Bank of America Merrill Lynch 2012 Healthcare Conference
5/16/12 8:00 am EDT
Dr. Scholl's® Survey Reveals America is on the Move When Foot Pain Doesn't Get in the Way
5/10/12 9:08 am EDT
Merck to Present at Deutsche Bank 37th Annual Health Care Conference
5/8/12 8:00 am EDT
COPPERTONE® Launches Nationwide Contest in Search of Modern Little Miss Coppertone
5/3/12 8:08 am EDT
Merck Wins U.S. ZETIA® (ezetimibe)/ VYTORIN® (ezetimibe/simvastatin) Patent Infringement Lawsuit
4/27/12 6:05 pm EDT
Merck Presents Results of a Phase I Clinical Trial Evaluating Investigational BACE inhibitor MK-8931 at American Academy of Neurology
4/27/12 8:08 am EDT
Merck Announces First-Quarter 2012 Financial Results
4/27/12 7:00 am EDT
Merck_Supplemental_Earnings_Package_1Q12.pdf (279.09 KB)
Opportunity’s Knocking – Are Young Adult Women Prepared?
4/26/12 8:08 am EDT
Merck Named as Leader in Maplecroft Climate Innovation Index
4/24/12 8:08 am EDT
Merck and RESOLVE Remind Couples That a Conversation with a Specialist Could Be The Start of Something Small
4/23/12 8:08 am EDT
Merck Reports Phase III Study Results Evaluating Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy
4/19/12 7:00 am EDT
Merck Wins Another FOSAMAX® (alendronate sodium) State Court Trial
4/18/12 3:42 pm EDT
Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)
4/16/12 7:06 am EDT
New Data Analyses for VICTRELIS™ (boceprevir) Will Be Presented at The International Liver Congress™ / 2012 EASL Annual Meeting
4/4/12 8:08 am EDT
Randy Jackson Partners with Merck to Urge People with Type 2 Diabetes to Take Their Diabetes to Heart
4/3/12 8:08 am EDT
Efficacy and Safety Data for ZOSTAVAX® (Zoster Vaccine Live), Merck's Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases
4/2/12 9:04 am EDT
Merck Appoints Michael J. Holston as Chief Ethics and Compliance Officer
3/28/12 9:30 am EDT
Merck to Hold First-Quarter 2012 Sales and Earnings Conference Call on April 27
3/27/12 8:00 am EDT
In TRA-2P Study, Adding Merck's Vorapaxar to Standard of Care Significantly Reduced the Risk of Cardiovascular Events
3/24/12 9:10 am EDT
Merck and Safe Water Network Launch Initiative to Improve Water Access and Help Reduce the Impact of Water-Borne Disease in India
3/20/12 8:08 am EDT
Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research (Calibr)
3/15/12 8:00 am EDT
Merck to Present at the Barclays Capital 2012 Global Healthcare Conference
3/13/12 8:00 am EDT
Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1
3/6/12 8:14 pm EST
Merck Confirms 2012 Full-Year Guidance
3/6/12 8:00 am EST
Merck’s Investigational Allergy Immunotherapy Tablet (AIT) Significantly Reduced the Combination of Ragweed Allergy Symptoms and Medication Use in Phase III Trial
3/5/12 8:30 am EST
Merck Receives 2012 ENERGY STAR® Sustained Excellence Award From U.S. Environmental Protection Agency (EPA)
3/5/12 8:08 am EST
Merck to Present at the Cowen & Company 32nd Annual Health Care Conference
3/5/12 8:00 am EST
Merck Announces Second-Quarter 2012 Dividend
2/28/12 1:36 pm EST
Merck to Present at the 2012 Citi Global Healthcare Conference
2/28/12 8:30 am EST
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey
2/27/12 8:08 am EST
Singer Jon Secada Joins Merck and American Liver Foundation's 'Tune In to Hep C' Public Awareness Campaign
2/16/12 8:08 am EST
Merck Establishes Joint Venture with Supera Farma to Commercialize Innovative Pharmaceutical Products and Branded Generics in Brazil
2/15/12 7:00 am EST
Merck to Present at the Leerink Swann 2012 Global Healthcare Conference
2/14/12 8:30 am EST
FDA Approves ZIOPTAN™ (tafluprost ophthalmic solution), Merck’s Once-Daily, Preservative-Free Ophthalmic Medication
2/13/12 10:15 am EST
Kentucky Court Of Appeals Reverses Certification of a Class of Plaintiffs Seeking Reimbursement for Vioxx® Costs
2/10/12 8:08 am EST
Thomas E. Shenk To Retire From Merck's Board of Directors
2/8/12 3:00 pm EST
Merck Informs U.S. Physicians of Results of Drug Interaction Study of Co-Administration of VICTRELIS™ with Ritonavir-Boosted HIV Protease Inhibitors
2/8/12 8:08 am EST
Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar
2/7/12 8:30 am EST
The NAMES Project Foundation and Merck Launch "Call My Name" National Tour AIDS Panel Making Workshop to Focus Attention on HIV/AIDS Crisis in African American Communities
2/7/12 8:08 am EST
Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia
2/6/12 8:45 am EST
FDA Approves JANUMET® XR (sitagliptin and metformin HCl extended-release) for Type 2 Diabetes, Offering the Powerful Efficacy of JANUMET® (sitagliptin/metformin HCl) Now Available with Once-Daily Convenience
2/2/12 2:44 pm EST
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
2/2/12 7:00 am EST
MRK_Supplemental_Earnings_Package_4Q11.pdf (353.15 KB)
Reminder: Merck to Hold 2011 Full-Year and Fourth-Quarter Sales and Earnings Conference Call on February 2
1/26/12 8:00 am EST
New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
1/25/12 8:30 am EST
Merck Resolves Vioxx® Litigation in Canada
1/19/12 8:08 am EST
Merck to Present at the 30th Annual J.P. Morgan Healthcare Conference
1/9/12 8:30 am EST
FDA Approves Merck’s ISENTRESS® (raltegravir) for Use in Children Ages Two Years and Older as Part of HIV-1 Combination Therapy
1/6/12 8:08 am EST
Merck to Present at Goldman Sachs 2012 Healthcare Event
1/4/12 8:30 am EST
Merck and the ADAP Crisis Task Force Announce New Agreement to Improve Access and Care for People with HIV
12/21/11 11:19 am EST
Merck Announces Initiation of Clinical Development Collaboration with Roche To Evaluate Investigational Combination Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Infection
12/15/11 8:08 am EST
Merck Announces Results of ZOLINZA® (vorinostat) Phase III and IIb Trials for Investigational Use for Multiple Myeloma at American Society of Hematology Annual Meeting
12/12/11 8:08 am EST
Merck Establishes New MSD R&D Asia Headquarters
12/6/11 1:30 am EST
Merck for Mothers and PATH Collaborate to Identify Innovations that Save Mothers' Lives
12/5/11 8:08 am EST
Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney’s Office for the District of Massachusetts Related to Vioxx®
11/22/11 3:23 pm EST
Data from TRACER Study of Vorapaxar, Merck's Investigational Medicine for Cardiovascular Disease, Presented at AHA and Published in NEJM
11/13/11 8:05 am EST
Merck and Partners Make Progress In Long-Term Commitment to End River Blindness
11/11/11 8:08 am EST
Merck to Present at the 2011 Credit Suisse Healthcare Conference
11/10/11 5:00 pm EST
Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&D and Business Briefing
11/10/11 9:55 am EST
Merck Executing on Strategy to Position Company for Long-Term Sustainable Growth
11/10/11 8:55 am EST
Merck Launches NEXPLANON® (etonogestrel implant) 68 mg in the United States – A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years
11/9/11 9:00 am EST
Interim Data for Merck's VICTRELISTM (boceprevir) in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1 to be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
11/5/11 9:00 am EDT
FDA Advisory Committee Unanimously Recommends Approval of Merck's VYTORIN® (ezetimibe/simvastatin) for Use in Patients with Pre-Dialysis Chronic Kidney Disease
11/2/11 5:36 pm EDT
Merck Announces Dates for R&D and Business Briefing and Fourth-Quarter 2011 Sales and Earnings Report
10/31/11 4:30 pm EDT
Merck Announces Third Quarter 2011 Financial Results
10/28/11 7:00 am EDT
MRK_Supplemental_Earnings_Package_3Q11.pdf (321.35 KB)
New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males
10/26/11 5:35 pm EDT
CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men
10/25/11 2:17 pm EDT
Merck Announces Presentation of Phase III Investigational Studies Evaluating DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
10/24/11 4:30 pm EDT
Interim Phase IIb Data for Merck's VICTRELIS™ (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting
10/20/11 8:00 am EDT
Merck’s ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1
10/13/11 8:00 am EDT
FDA Approves Merck’s JUVISYNC™ (sitagliptin and simvastatin) Tablets, a Once-Daily Therapy for Patients with Type 2 Diabetes Who Need to Lower Blood Sugar and Cholesterol, Known Risk Factors for Cardiovascular Disease
10/7/11 7:53 pm EDT
Merck Announces Retirement of Chairman and Former CEO Richard T. Clark
10/6/11 11:15 am EDT
FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor
10/5/11 7:35 am EDT
Merck Adds New Medication Adherence Resources to Consumer Web Site
10/4/11 8:00 am EDT
Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX® (alendronate sodium)
10/3/11 11:54 am EDT
Merck Announces New Data Analyses for VICTRELIS™ (boceprevir) will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
9/30/11 10:55 am EDT
Merck to Hold Third-Quarter 2011 Sales and Earnings Conference Call on October 28
9/30/11 8:00 am EDT
Merck Publishes 2010 Global Corporate Responsibility Report
9/30/11 8:00 am EDT
Merck Sells Its Interest in Johnson & Johnson-Merck Consumer Pharmaceuticals
9/28/11 4:10 pm EDT
Merck Names Cuong Viet Do as Chief Strategy Officer
9/27/11 8:30 am EDT
Study of ZOLINZA® (vorinostat) for Investigational Use for Advanced Malignant Pleural Mesothelioma Did Not Meet Primary Endpoint
9/23/11 8:00 am EDT
Merck Joins Global Fight to Help Save Women's Lives During Pregnancy and Childbirth
9/20/11 8:00 am EDT
New Data on Odanacatib, Merck’s Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research
9/19/11 5:40 pm EDT
Merck’s ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race
9/19/11 8:00 am EDT
Merck to Present at Bank of America Merrill Lynch Global Healthcare Conference
9/14/11 8:00 am EDT
Merck Partners with Susan G. Komen for the Cure® on Historic Initiative to Help Address Cervical and Breast Cancer in Developing Nations
9/13/11 9:03 am EDT
Merck and BGI Establish Strategic Collaboration focused on Biomarkers and Genomic Technologies
9/13/11 12:05 am EDT
Merck to Present at Morgan Stanley Global Healthcare Conference
9/12/11 8:00 am EDT
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial
9/7/11 8:08 am EDT
Texas Supreme Court Finds for Merck in VIOXX® Case
8/26/11 8:08 am EDT
Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health
8/23/11 8:00 am EDT
Merck Announces Second Quarter 2011 Financial Results
7/29/11 7:00 am EDT
MRK_Supplemental_Earnings_Package_2Q11.pdf (378.1 KB)
Merck Recognizes World Hepatitis Day With Partnerships and Grants to Support Global Hepatitis C Community
7/28/11 8:08 am EDT
Latest Merck Manual Delivers Trusted Health Care Information in Print and Electronic Formats
7/27/11 8:08 am EDT
Merck Announces Fourth Quarter 2011 Dividend
7/26/11 1:44 pm EDT
R&B Legend Natalie Cole Joins Rock Legend Gregg Allman, Merck and The American Liver Foundation to Turn Up the Volume Around Hep C
7/26/11 8:08 am EDT
Merck and Simcere Sign Agreement to Establish Pioneering China Joint Venture
7/21/11 6:00 pm EDT
Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C
7/20/11 7:00 am EDT
Merck to Hold Second-Quarter 2011 Sales and Earnings Conference Call on July 29
6/30/11 8:00 am EDT
Merck Announces New Name for its Animal Health Division
6/29/11 8:08 am EDT
UPS and Merck Expand Their Distribution and Logistics Agreement
6/28/11 7:00 am EDT
Legendary Musician Gregg Allman Joins Merck and American Liver Foundation to Launch Tune In to Hep C Public Awareness Campaign
6/21/11 8:08 am EDT
Actress JoAnna Garcia Swisher "Goes There" in a New Campaign with Merck to Motivate Women to "Get Real" When Talking to Their Physicians about Their Health
6/8/11 8:08 am EDT
Merck to Present at Goldman Sachs 32nd Annual Healthcare Conference
6/7/11 8:00 am EDT
Roche and Merck Collaborate to Develop Diagnostic Tests for Merck’s Investigational Cancer Therapies
6/7/11 7:30 am EDT
Merck Commends GAVI Alliance on Continued Efforts to Improve Access
6/5/11 8:08 am EDT
Merck Signs on to United Nations CEO Water Mandate
6/2/11 8:08 am EDT
Merck to Present at Sanford Bernstein 27th Strategic Decisions Conference
5/31/11 8:00 am EDT
Merck Announces Third Quarter 2011 Dividend
5/24/11 11:24 am EDT
Merck and Roche Establish Strategic Agreements in Fight Against Chronic Hepatitis C
5/17/11 11:30 am EDT
Merck Completes Acquisition of Inspire Pharmaceuticals, Inc.
5/16/11 11:30 am EDT
Merck Announces Successful Completion of Tender Offer for Shares of Inspire Pharmaceuticals, Inc. With Over 75 Percent of Shares Tendered
5/13/11 8:30 am EDT
Merck Announces Hope Against Hepatitis C Initiative to Support Public Awareness, Education and Research in the Fight Against Hepatitis C Virus
5/9/11 8:30 am EDT
Merck to Present at Deutsche Bank 36th Annual Healthcare Conference
5/2/11 8:00 am EDT
Merck Announces First Quarter 2011 Financial Results
4/29/11 7:00 am EDT
MRK_Supplemental_Earnings_Package_1Q11.pdf (291.63 KB)
Merck and Inspire Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire
4/28/11 8:30 am EDT
Merck Announces New $5 Billion Share Repurchase Program
4/27/11 7:45 am EDT
Merck Commences Tender Offer for all Outstanding Shares of Inspire Pharmaceuticals, Inc.
4/15/11 9:01 am EDT
Merck Reaffirms 2011 Non-GAAP EPS Target
4/15/11 7:01 am EDT
Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE® and SIMPONI®
4/15/11 7:00 am EDT
Merck & Co., Inc., and Sun Pharma Establish Joint Venture to Develop and Commercialize Novel Formulations and Combinations of Medicines in Emerging Markets
4/11/11 8:01 am EDT
Merck to Acquire Inspire Pharmaceuticals, Inc.
4/5/11 9:30 am EDT
Merck to Hold First-Quarter 2011 Sales and Earnings Conference Call on April 29
4/1/11 1:00 pm EDT
Jury Finds for Merck and Other Defendants on the Key Issue in an Environmental Contamination Lawsuit
3/31/11 8:08 am EDT
Merck and sanofi-aventis to Maintain Separate Businesses in Animal Health
3/22/11 2:00 am EDT
Merck Receives 2011 ENERGY STAR® Sustained Excellence Award From U.S. Environmental Protection Agency (EPA)
3/16/11 8:08 am EDT
Merck to Present at Barclays Capital 2011 Global Healthcare Conference
3/15/11 8:00 am EDT
SisterLove, Inc. and Merck Launch "Everyone Has A Story" Series
3/10/11 8:08 am EST
Merck to Present at Cowen and Company's 31st Annual Health Care Conference
3/7/11 8:00 am EST
Merck to Present at Citi 2011 Global Health Care Conference
2/28/11 2:00 pm EST
Fujifilm to Acquire Merck Biomanufacturing Network
2/28/11 12:01 am EST
Merck Announces Second Quarter 2011 Dividend
2/22/11 3:54 pm EST
Merck Wins First FOSAMAX® (alendronate sodium) State Court Trial
2/14/11 11:07 am EST
Merck Announces Fourth Quarter and Full Year 2010 Financial Results
2/3/11 7:00 am EST
John J. Horan, Former Merck Chairman and CEO Dies of Natural Causes at 90 Years of Age
1/25/11 4:23 pm EST
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in New Jersey State Court
1/18/11 8:08 am EST
Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates
1/12/11 7:30 am EST
Merck to Present at the 29th Annual J.P. Morgan Healthcare Conference
1/11/11 8:00 am EST
Merck to Hold Fourth-Quarter 2010 Sales and Earnings Conference Call on Feb. 3
1/4/11 7:11 pm EST
Merck Prices $2.0 Billion Debt Offering
12/7/10 5:14 pm EST
Merck to Acquire SmartCells, Inc.
12/2/10 7:41 am EST
Merck Board Elects Kenneth C. Frazier as Next CEO; Richard T. Clark to Continue as Chairman
11/30/10 7:00 am EST
Merck Announces First-Quarter 2011 Dividend
11/23/10 3:29 pm EST
Merck Wins Another Federal FOSAMAX® (alendronate sodium) Bellwether Trial
11/19/10 5:56 pm EST
Merck and Partners Make Progress in Long-Term Commitment to End River Blindness
11/11/10 8:30 am EST
Merck Wins TEMODAR® Patent Infringement Lawsuit on Appeal
11/9/10 2:46 pm EST
Merck Announces Third-Quarter 2010 Financial Results
10/29/10 7:00 am EDT
3Q10_Supplemental_Earnings_Package.pdf (370.44 KB)
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court
10/28/10 8:08 am EDT
Weight Watchers and Merck Collaborate to Help Physicians Fight Obesity Through Lifestyle Management Approach
10/13/10 8:08 am EDT
Tenth Edition of The Merck Veterinary Manual Debuts
10/13/10 8:08 am EDT
Lundbeck and Merck Sign Exclusive Commercialization Agreement for SYCREST® (asenapine) Sublingual Tablets in All Markets Outside of the United States, China and Japan
10/12/10 5:00 am EDT
Merck to Appeal Reduced Jury Verdict in Federal FOSAMAX® (alendronate sodium) Case
10/4/10 4:10 pm EDT
Merck to Hold Third-Quarter 2010 Sales and Earnings Conference Call on Oct. 29
10/1/10 8:30 am EDT
Merck to Appeal Verdict in Massachusetts Medicaid Case
9/30/10 4:05 pm EDT
Why So Shy? What Females of the Facebook Generation Are Not Sharing in the OB/GYN Office that Could Affect Their Health
9/29/10 8:08 am EDT
Merck Significantly Expands its Patient Assistance Program Offerings to Provide Access to More Medicines for People in Need
9/22/10 8:30 am EDT
Merck's Non-Profit to Advance Science Education Joins President Obama's Educate to Innovate Campaign
9/16/10 8:30 am EDT

By Category

More Prescription Medicine News

Consumer Care News

Merck and Celebrity Chef Art Smith “Cook Up a Recipe” for Better Type 2 Diabetes Management
5/7/13 10:33 am EDT
FDA Approves OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women
1/25/13 11:30 am EST
Dr. Scholl's® Survey Reveals America is on the Move When Foot Pain Doesn't Get in the Way
5/10/12 9:08 am EDT
COPPERTONE® Launches Nationwide Contest in Search of Modern Little Miss Coppertone
5/3/12 8:08 am EDT

More Consumer Care News

Vaccine News

More Vaccine News

Research and Development News

More Research & Development News

Corporate News

Merck Announces $5 Billion Accelerated Share Repurchase
5/21/13 5:00 pm EDT
Merck to Present at the UBS Global Healthcare Conference
5/17/13 3:45 pm EDT
Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently
5/17/13 8:30 am EDT
Merck Prices $ 6.5 Billion Debt Offering
5/15/13 6:29 pm EDT

More Corporate News

Financial News

Merck Announces $5 Billion Accelerated Share Repurchase
5/21/13 5:00 pm EDT
Merck to Present at the UBS Global Healthcare Conference
5/17/13 3:45 pm EDT
Merck Prices $ 6.5 Billion Debt Offering
5/15/13 6:29 pm EDT
Merck to Present at the Bank of America/Merrill Lynch 2013 Healthcare Conference
5/14/13 9:15 am EDT

More Financial News

Corporate Responsibility News

Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently
5/17/13 8:30 am EDT
Merck for Mothers Launches Initiative in India to Reduce the Number of Women Dying During Pregnancy and Childbirth
5/14/13 4:23 pm EDT
Bruce Kuhlik and Merck Honored by PBI for Commitment to Pro Bono
2/28/13 9:43 am EST
Renowned Photographer and HIV Activist Duane Cramer Partners with Project Runway Star Mondo Guerra and Merck on I Design Campaign
2/7/13 9:04 am EST

More Corporate Responsibility News

Patients & Caregivers
Healthcare Professionals
- EngageZone
- The Merck Manual
- Merck Medicus
- Authorized Distributors
- Clinical Trials
- Supplier Diversity
Media & Investors
Job Seekers
Company Statements

Privacy
Terms of Use
Site Map

Business Wire NewsHQ℠

Newsroom

By Date

By Category

Consumer Care News

Vaccine News

Research and Development News

Corporate News

Financial News

Corporate Responsibility News

SEARCH NEWSROOM

Patients & Caregivers

Healthcare Professionals

Suppliers

Media & Investors

Job Seekers

Company Statements

Podcasts

RSS